<?xml version="1.0" encoding="UTF-8" standalone="no" ?>
<rss version="2.0">
  <channel>
    <title>Lamm, M.</title>
    <link>http://repub.eur.nl/res/aut/12548/</link>
    <description>List of Publications</description>
    <language>en</language>
    <image>
      <url>http://repub.eur.nl/static-eur/img/logo.png</url>
      <title>RePub, Erasmus University Rotterdam</title>
      <link>http://repub.eur.nl</link>
    </image>
    <item>
      <title>Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial (Article)</title>
      <link>http://repub.eur.nl/res/pub/8286/</link>
      <pubDate>2004-01-01T00:00:00Z</pubDate>
      <description>BACKGROUND: Helicobacter pylori gastritis may progress to glandular
      atrophy and intestinal metaplasia, conditions that predispose to gastric
      cancer. Profound suppression of gastric acid is associated with increased
      severity of H pylori gastritis. This prospective randomised study aimed to
      investigate whether H pylori eradication can influence gastritis and its
      sequelae during long term omeprazole therapy for gastro-oesophageal reflux
      disease (GORD). METHODS: A total of 231 H pylori positive GORD patients
      who had been treated for &gt; or =12 months with omeprazole maintenance
      therapy (OM) were randomised to either continuation of OM (OM only; n =
      120) or OM plus a one week course of omeprazole, amoxycillin, and
      clarithromycin (OM triple; n = 111). Endoscopy with standardised biopsy
      sampling as well as symptom evaluation were performed at baseline and
      after one and two years. Gastritis was assessed according to the Sydney
      classification system for activity, inflammation, atrophy, intestinal
      metaplasia, and H pylori density. RESULTS: Corpus gastritis activity at
      entry was moderate or severe in 50% and 55% of the OM only and OM triple
      groups, respectively. In the OM triple group, H pylori was eradicated in
      90 (88%) patients, and activity and inflammation decreased substantially
      in both the antrum and corpus (p&lt;0.001, baseline v two years). Atrophic
      gastritis also improved in the corpus (p&lt;0.001) but not in the antrum. In
      the 83 OM only patients with continuing infection, there was no change in
      antral and corpus gastritis activity or atrophy, but inflammation
      increased (p&lt;0.01). H pylori eradication did not alter the dose of
      omeprazole required, or reflux symptoms. CONCLUSIONS: Most H pylori
      positive GORD patients have a corpus predominant pangastritis during
      omeprazole maintenance therapy. Eradication of H pylori eliminates gastric
      mucosal inflammation and induces regression of corpus glandular atrophy. H
      pylori eradication did not worsen reflux disease or lead to a need for
      increased omeprazole maintenance dose. We therefore recommend eradication
      of H pylori in GORD patients receiving long term acid suppression.</description>
    </item>
  </channel>
</rss>